

Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI)



Alaide Chieffo^{1*}, MD; Giuseppe Tarantini², MD; Christoph Naber³, MD; Emanuele Barbato^{4,5}, MD; Marco Roffi⁶, MD; Giulio G. Stefanini^{7,8}, MD; Gill Louise Buchanan⁹, MD; Piotr Buszman¹⁰, MD; Raul Moreno¹¹, MD; Barbara Zawisłak¹², MD; Guillaume Cayla¹³, MD; Haim Danenberg¹⁴, MD; Joao Antonio Brum Da Silveira¹⁵, MD; Holger Nef¹⁶, MD; Stefan James¹⁷, MD; Josepa Mauri Ferre¹⁸, MD; Michiel Voskuil¹⁹, MD; Nils Witt²⁰, MD; Stephan Windecker²¹, MD; Andreas Baumbach^{22,23}, MD; Dariusz Dudek^{24,25}, MD

1. Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy; 2. Interventional Cardiology Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy; 3. Medizinische Klinik I, Kardiologie und Intensivmedizin, Klinikum Wilhelmshaven, Wilhelmshaven, Germany; 4. Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy; 5. Cardiovascular Research Center Aalst, Aalst, Belgium; 6. Division of Cardiology, University Hospitals, Geneva, Switzerland; 7. Humanitas Clinical and Research Hospital IRCCS, Rozzano, Milan, Italy; 8. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 9. Department of Cardiology, North Cumbria Integrated Care NHS Foundation Trust, Cumbria, United Kingdom; 10. Cardiology Department, Andrzej Frycz-Modrzewski Kraków University, American Heart of Poland, Bielsko-Biala, Poland; 11. Cardiology Department, Hospital La Paz and IDIPAZ, Madrid, Spain; 12. Intensive Cardiac Care Unit, University Hospital Kraków, Kraków, Poland; 13. Department of Cardiology, CHU Nimes, Montpellier University, Nimes, France; 14. Interventional Cardiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; 15. Centro Hospitalar e Universitário do Porto, Hospital de Santo António, Porto, Portugal; 16. Department of Cardiology and Angiology, University of Giessen, Giessen, Germany; 17. Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden; 18. Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 19. Interventional Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, the Netherlands; 20. Department of Clinical Science and Education, Karolinska Institute, Division of Cardiology, Södersjukhuset, Stockholm, Sweden; 21. Department of Cardiology, Inselspital University Hospital Bern, Bern, Switzerland; 22. Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, Barts Heart Centre, London, United Kingdom; 23. Yale University School of Medicine, New Haven, CT, USA; 24. Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 25. Maria Cecilia Hospital GVM, Cotignola, Ravenna, Italy

This paper also includes supplementary data published online at: <https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-20-01291>

KEYWORDS

- miscellaneous
- stable angina
- COVID-19

Abstract

The rearrangement of healthcare services required to face the coronavirus disease 2019 (COVID-19) pandemic led to a drastic reduction in elective cardiac invasive procedures. We are already facing a “second wave” of infections and we might be dealing during the next months with a “third wave” and subsequently new waves. Therefore, during the different waves of the COVID-19 pandemic we have to face the problems of how to perform elective cardiac invasive procedures in non-COVID patients and which patients/procedures should be prioritised. In this context, the interplay between the pandemic stage, the availability of healthcare resources and the priority of specific cardiac disorders is crucial. Clear pathways for “hot” or presumed “hot” patients and “cold” patients are mandatory in each hospital. Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test patients for SARS-CoV-2 infection before the interventional procedure, regardless of risk assessment for COVID-19. Pre-hospital testing should always be conducted in the presence of symptoms suggestive of SARS-CoV-2 infection. In cases of confirmed or suspected COVID-19 positive patients, full personal protective equipment using FFP 2/N95 masks, eye protection, gowning and gloves is indicated during cardiac interventions for healthcare workers. When patients have tested negative for COVID-19, medical masks may be sufficient. Indeed, individual patients should themselves wear medical masks during cardiac interventions and outpatient visits.

*Corresponding author: Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milan, Italy. E-mail: chieffo.alaide@hsr.it

Abbreviations

ACS	acute coronary syndrome
AGPs	aerosol generating procedures
COVID-19	coronavirus disease 2019
ED	emergency department
HCWs	healthcare workers
NSTEMI	non-ST-elevation myocardial infarction
PPCI	primary percutaneous coronary intervention
PPE	personal protective equipment
STEMI	ST-elevation myocardial infarction

Introduction

The rearrangement of healthcare services required to face the coronavirus disease 2019 (COVID-19) pandemic led to drastic reductions of elective cardiac invasive procedures¹. Regions in Europe differ substantially in terms of local healthcare resources, pandemic extent, phase of the COVID-19 outbreak, changes of the pandemic over time and therefore access to healthcare services other than COVID-19 care. During the “first wave”, these variations had a wide range of implications for regional healthcare services, national healthcare authorities and in-hospital redistribution of resources.

We are now in a phase of the COVID-19 pandemic whereby some countries are already facing a “second wave” of infections and we might be dealing during the coming months with a “third wave” and subsequently new waves of infection. Therefore, we have to face the problems of how to perform elective cardiac invasive procedures in non-COVID patients and which patients/procedures should be prioritised during the different waves of the COVID-19 pandemic². Simultaneously, during these phases, protocols that provide maximum safety of patients and healthcare workers (HCWs) during the hospitalisation and procedures require to be designed. The European Association of Percutaneous Cardiovascular Interventions (EAPCI) has assembled a panel of interventional cardiologists with first-hand experience from affected areas, representatives of heavily, moderately and marginally affected countries and expertise in network organisation. The objective of this position statement is to define algorithms for safe performance of elective cardiac procedures according to the local extent and phase of the pandemic and available resources to prioritise patient work-up and procedures.

This statement reflects the official position of the EAPCI, meant to provide an overall guidance that should be adapted to the local situation and regulations.

IMPACT OF EPIDEMIOLOGIC VARIATIONS AMONG COUNTRIES ON CARDIAC INVASIVE PROCEDURES DURING THE COVID-19 OUTBREAK

The epidemiologic situation was not uniform within each individual European country, suggesting that considerations should be made at regional rather than at national levels. Despite these premises, the responses of the healthcare systems to the “first wave” were rather uniform and in line with the EAPCI strategic

categorisation of cardiovascular interventions¹. Healthcare systems were re-organised to separate as much as possible “hot” (dedicated to positive or suspected COVID-19 patients) from “cold” pathways (COVID-19 negative). In some regions, this occurred at the hospital level, with fully dedicated COVID-19 hospitals, while in others the separation was done within the same hospital, with COVID-19 dedicated wards and catheterisation laboratories³. In this latter case, the access and in-hospital path of the COVID-19 patients was, in general, physically separated from the path of the other patients. Given the often occult presentation of COVID-19, characterised by delayed clinical presentation from the time of contagion, at times with complete lack of symptoms, “cold” sites were sometimes affected by infections within the workforce and asymptomatic patients. This led to recurrent and temporary closures of the cold sites, disinfection, quarantine of the HCWs and patients involved, with a major impact on the regular healthcare services.

Elective structural and coronary procedures were in general put on hold and/or postponed during the “first wave” in order to increase the critical mass of HCWs available and to free intensive care unit (ICU) beds for patients with severe COVID-19 pneumonia requiring mechanical ventilation⁴. Acute cardiovascular procedures, mostly in patients with ST-elevation myocardial infarction (STEMI) and unstable or high-risk non-ST-elevation myocardial infarction (NSTEMI), were overall preserved. Interestingly, a general trend of 20-50% fewer STEMI cases was observed in many regions, which could be a consequence of the public campaign requesting the population “to stay at home”. Other factors linked to the lockdown (e.g., reduced pollution, reduced physical activity and stress, etc.) are also discussed in this context⁵⁻⁷. Importantly, HCWs reported a surge of mechanical complications of STEMI, most probably related to delayed presentation of the patients, and less frequently to a shift in the reperfusion therapy towards thrombolysis in some circumstances⁸⁻¹¹.

While most healthcare systems returned to a certain routine clinical activity after the “first wave” of the pandemic with resumption of elective cardiovascular procedures, we are already facing the “second wave” of infections, and we cannot exclude that we may be facing new waves of infections in the upcoming months. In this position statement only elective invasive cardiac procedures for non-COVID patients will be discussed, since emergent procedures have been discussed previously¹.

KEY MESSAGES

- The EAPCI position to postpone cardiovascular procedures in stable patients to unload HCWs and intensive care beds during the “first wave” of the COVID-19 pandemic was aligned with most European healthcare system recommendations.
- While most healthcare systems returned to a certain level of routine clinical activity with resumption of elective cardiovascular procedures, we are now facing the “second wave” or new waves of infections.

PERFORMING ELECTIVE CARDIAC INVASIVE PROCEDURES TAKING INTO ACCOUNT THE PANDEMIC STAGE, RESOURCES AND PATIENTS/PROCEDURES TO PRIORITISE

The invasive management of acute coronary syndromes during the COVID-19 pandemic is beyond the scope of this document and has been covered elsewhere¹. Recovery plans of elective procedures should consider three different variables:

1. Pandemic stage.
2. Availability of healthcare resources (including capacity of ICUs).
3. Patients/procedures to prioritise.

The pandemic stage in a given region should be quantified taking into account the number of infections per thousand people, the “growth rate”, number of cases requiring hospitalisation in general wards and ICUs per thousand people, and the degrees of transmission classified into the following categories according to World Health Organization (WHO) recommendation:

- a. No case: with no confirmed case.
- b. Sporadic cases: with one or more cases, imported or locally detected.
- c. Cluster of cases: experiencing cases, clustered in time, geographic location and/or by common exposures.
- d. Community transmission: experiencing larger outbreaks of local transmission defined through an assessment of factors including, but not limited to: large numbers of cases not linkable to transmission chains; large numbers of cases from sentinel lab surveillance; and/or multiple unrelated clusters in several areas of the country/territory/area.

Of note, the estimation of the “growth rate” is heavily influenced by the testing strategy and the test capacity in different regions; therefore, the evaluation of the number of hospitalised patients remains crucial to identify the degree of COVID-19 transmission and to scale the catheterisation laboratories’ capacity for elective cases.

The availability of healthcare resources should be assessed essentially by taking into account (net of any re-allocation) the

number of beds in non-ICUs and ICUs per population, as well as the number of ventilators, amount of personal protective equipment (PPE), number of HCWs and budget resources to invest. A recommended threshold of available ICU capacity should be provided by regional institutions.

The third parameter (patients/procedures to prioritise) includes a careful evaluation of the number of patients on waiting lists and the accumulated delay, as well as the type of the cardiovascular disease requiring invasive procedures and the severity of symptoms (risk of mortality, morbidity and hospitalisation of that patient in the short and medium term, if not treated), and other patient conditions (age and comorbidities) impacting on the length of stay after intervention. Procedures could be divided into three levels: urgent (to be performed within days), semi-urgent (to be performed within <3 months) and elective (could be postponed beyond 3 months)^{2,12-14}.

Table 1 summarises cardiac conditions requiring invasive procedures according to these levels. The use of potential alternatives to invasive angiography (e.g., coronary computed tomography) should be taken into account whenever possible.

From the interdependence of these three variables, different clinical scenarios in planning elective invasive procedures can be assumed in non-COVID patients during different waves of infection. The worst situation occurs when the majority of available healthcare resources are dedicated to the COVID-19 pandemic in countries experiencing new waves of infections. In this scenario, cardiac invasive procedures should be performed after a careful assessment of the risk/benefit profile. On the other hand, in the best possible clinical scenario, when the number of infections is low and/or the impact on hospital resources is trivial, all invasive cardiac procedures can be planned.

Detailed suggestions on how to plan elective invasive procedures according to the interplay between the local stage of the pandemic, the expected impact on hospital resources, and the priority of specific cardiac disorders are summarised in **Table 2** and **Figure 1**.




Figure 1. Decisional algorithm on how to perform elective invasive procedures according to the priority of cardiac disorders and the interplay among different stages of the pandemic and hospital resource availability. Urgent: to be performed within days. Semi-urgent: to be performed within <3 months. Elective: could be performed beyond 3 months.

Table 1. Elective cardiac invasive procedures classified according to the priority level.

Clinical condition	Urgent* (to be performed within days)	Semi-urgent (to be performed within <3 months)	Elective (could be performed beyond 3 months)
Ischaemic heart disease	Coronary angiogram/PCI for CCS 4 angina	Coronary angiogram/PCI for CCS 3 stable angina or NYHA III symptoms	Coronary angiogram/PCI for CCS 2 stable angina, silent ischaemia or NYHA II symptoms
	Left main PCI/last remaining vessel PCI	Proximal LAD PCI	CTO interventions
	Coronary angiogram/PCI diagnostic catheterisation for decompensated ischaemic HF	Coronary angiogram/PCI diagnostic catheterisation for symptomatic LV dysfunction	Coronary angiogram/PCI/diagnostic catheterisation for asymptomatic LV dysfunction
	Staged PCI of non-IRA in STEMI in patients with >90% lesions in proximal segments of major epicardial coronary arteries	Staged PCI of non-IRA in STEMI in patients with haemodynamic stability and without >90% lesions in proximal segments of major epicardial coronary arteries	
Valvular heart disease	Diagnostic cath/TAVI for decompensated SAS (NYHA IV, recurrent syncope, rest/unstable angina)	Diagnostic cath/TAVR for symptomatic SAS due to NYHA III, or NYHA ≥II AND LV impairment, or recent syncope	Diagnostic cath/TAVR for SAS with NYHA II
	Diagnostic cath/TMVR for symptomatic severe MR with haemodynamic instability or refractory HF with NYHA IV	Diagnostic cath/TMVR for symptomatic severe MR due to refractory HF with NYHA III or marked LV impairment	Diagnostic cath/TMVR for severe MR with stable HF
	Diagnostic cath/VIV procedures for symptomatic bioprosthesis degeneration with NYHA IV or other uncontrolled symptoms	Diagnostic cath/VIV procedures for symptomatic bioprosthesis degeneration with NYHA III or marked LV impairment	Diagnostic cath/VIV procedures for symptomatic bioprosthesis degeneration with NYHA II or NYHA I without marked LV impairment
	Diagnostic cath/TVR for other severe symptomatic valvular disease (AR, TR, MS) with NYHA IV or other uncontrolled symptoms	Diagnostic cath/TVR for other severe symptomatic valvular disease (AR, TR, MS) with NYHA III or marked LV impairment	Diagnostic cath/TVR for other severe valvular disease (AR, TR, MS) with NYHA II or NYHA I without marked LV impairment
Other interventions		LAA occlusion in unstable patients	LAA occlusion in stable patients
		PFO occlusion if ≥2 recurrent embolic events	Diagnostic cath/ASD occlusion/PFO occlusion/other interventions for congenital disease, alcohol septal ablation
		Transcatheter PVL occlusion in patients with HF and/or haemolysis	Reducer implantation
		Diagnostic cath/reversibility testing for pulmonary hypertension/congenital heart disease in NYHA III-IV	Diagnostic cath/reversibility testing for pulmonary hypertension/congenital heart disease in NYHA II
	EMB during the first early after heart transplantation (during the first two months)	EMB in other clinical conditions	

*Urgent procedures do not include the management of unstable/emergent patients. The invasive management of acute cardiac conditions has been treated elsewhere¹. AR: aortic regurgitation; ASD: atrial septal defect; CCS: Canadian Cardiovascular Society; CTO: chronic total occlusion; EF: ejection fraction; EMB: endomyocardial biopsy; HF: heart failure; IRA: infarct-related artery; LAA: left atrial appendage; LAD: left anterior descending coronary artery; LV: left ventricle; MS: mitral stenosis; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; PFO: patent foramen ovale; PVL: paravalvular leak; SAS: severe aortic stenosis; STEMI: ST-elevation myocardial infarction; TAVR: transcatheter aortic valve replacement; TMVR: transcatheter mitral valve replacement; TR: tricuspid regurgitation; TVR: transcatheter valve repair/replacement; VIV: valve-in-valve; VP: velocity peak

KEY MESSAGES

- Recovery plans for elective invasive procedures should consider the interplay between the pandemic stage, the availability of healthcare resources and the priority of specific cardiac disorders.
- All waiting list patients should be prioritised according to clinical criteria (severity of symptoms and disease) with a recurring evaluation if necessary (telemedicine/outpatient consultation).

WHICH PATIENTS AND PROCEDURES TO PRIORITISE

– FROM ETHICS TO EVIDENCE-BASED MEDICINE

The decision regarding which patients and procedures to prioritise is challenging, both from a medical and an ethical perspective,

and depends on the expected benefit from the procedure (survival vs symptomatic benefit), the degree of urgency required (urgent, semi-urgent and elective) as well as the available resources (HCWs, equipment, hospital beds, and financial resources) (**Table 1, Figure 2**).

The highest priority should be given to urgent procedures with documented prognostic benefit. These are described in **Table 1**¹⁵. Intermediate priority should indeed be given to semi-urgent procedures, as defined in **Table 1**.

Importantly, the benefit of a certain procedure should be put in the context of the individual patient and may range from maximum to limited or none, in terms of both life expectancy and quality of

Table 2. Indications on how to restart elective invasive procedures according to the interplay between the local stage of pandemic, the expected impact on hospital resources, and the priority of specific cardiac disorders.

	Healthcare resources		
	No ICU capacity or major restriction	Moderate restriction	Minor restriction or close to normal capacity
High prevalence/community transmission	Urgent procedures* (avoiding extreme risk)	Urgent/semi-urgent [†]	Urgent/semi-urgent [†]
Decreasing cases/clusters of cases	Urgent procedures* (avoiding extreme risk)	Urgent/semi-urgent [†]	Urgent/semi-urgent/elective [‡]
Low prevalence/sporadic cases	Urgent/semi-urgent [†]	Urgent/semi-urgent/elective [‡]	Urgent/semi-urgent/elective [‡]

Urgent procedures to be performed within days, semi-urgent to be performed within <3 months, and elective can be performed beyond 3 months.
 *Prefer a minimalist procedural approach according to local practice and early discharge whenever possible; Re-assess priority on a weekly basis with telemedicine evaluation; Consider outside referral; COVID-19 testing for all patients, PPE for all HCW; [†]Perform urgent/semi-urgent priority, following the waiting list; Re-assess priority on a weekly basis with telemedicine outpatient visits; COVID-19 testing for all patients, PPE for all HCW; [‡]Resume all invasive elective procedures, following the waiting list; COVID-19 testing for all patients, PPE for all HCW

Priority	Benefit from the procedure	Benefit in the individual patient	Timing indicated for the procedure	Available resources
Top	Survival benefit	Maximum	Emergent	Still limited due to the pandemic
↓		Symptomatic benefit	Limited	
	No benefit/futile		Elective	Back to normal
Low				

Figure 2. Interplay among expected benefit from the procedure, degree of urgency required and available resources in decision making on which patient and procedure to prioritise. Urgent: to be performed within days. Semi-urgent: to be performed within <3 months. Elective: could be performed beyond 3 months.

life. Factors such as age, comorbidities and life expectancy should also be taken into account during waves of the COVID pandemic where there is a paucity of beds, and similar considerations should also be taken into account in COVID-19 positive patients who are hospitalised for pneumonia.

While the estimated benefit from a specific procedure to the individual patient should be the first prioritisation criterion allowing the maximisation of the benefits, additional ethical criteria should guide the process of restarting an interventional activity. The process should be fair, meaning that within an institution, but ideally also within city and region, the criteria for decision making should be the same, though amongst different regions the restarting process may differ based on residual COVID-19 spread. Finally, patients should have the same access to cardiac procedures, regardless of medical insurance status, gender, ethnicity, and religious or political beliefs.

KEY MESSAGES

– The decision as to which patient and procedure to prioritise depends on the expected benefit from the procedure, the degree of urgency required and the available resources.

- The highest priority should be given to urgent procedures with documented prognostic benefit.
- Intermediate priority should be given to semi-urgent procedures.

MINIMISING PATIENT DELAY IN TREATMENT, WITH RESTORATION OF REASSURANCE AND SAFETY FOR BOTH PATIENTS AND HEALTHCARE WORKERS

The primary objective is to ensure the treatment of acute patients without delay, and to ensure that chronic patients are not left unsupported until their condition worsens.

The key priorities in the implementation of services during the COVID-19 outbreak are therefore twofold: first, to meet regional concerns about the reduced ability to progress with elective procedures due to social distancing, reduced capacity in the clinical areas available (some for reconfiguring of services, some to provide distance between patients), etc., and second, to reassure those individuals who require medical help that they will be treated safely.

Thus, communication is of particular importance, in particular since the precise instructions may change depending on the local and regional situation. In this context it is also important to highlight both the necessity to treat acute symptoms immediately and the fact that any delay in an acute cardiac situation can be fatal. This requires a combined effort from the public administration, scientific societies, hospitals, and referring physicians.

The appreciation of which measures are required to restore elective services in a responsible way will depend greatly on the local situation. If the local incidence of COVID-19 positive patients is low, attention will be directed much more to the clinical and epidemiologic side of the infection, while, in case of a high incidence, rigorous testing may be required.

Three objectives need to be considered:

1. To minimise the delay for the patients.
2. To ensure the separation of COVID-19 positive and negative patients.
3. To ensure the safety of the medical staff.

It is advisable, in the interest of the patients, to guarantee elective services, as soon as all parties assume that the local situation is favourable.

In any case, there need to be clear pathways for “hot” (COVID-19 positive) or presumed “hot” patients and “cold” patients in all hospitals (Figure 3). This can be achieved within the same institution or by the separation of “cold” centres for those routine patients with no risk of COVID-19. This latter organisation requires a regionally harmonised approach and specific attention to inter-institutional cooperation.




Figure 3. Hospital pathways during the COVID-19 pandemic for hot and cold areas. Patients with elective indications to percutaneous cardiac interventions undergo pre-hospital testing. If tested negative for COVID-19, they are admitted to cold areas (regular wards) of the hospital in order to undergo percutaneous cardiac interventions. If tested positive, according to symptoms, they will be sent to home isolation or admitted to hot areas (COVID-19 ward) in order to be treated for complications of the infection.

The implementation of pre-hospital triage is of utmost importance. This includes a symptom status questionnaire for all patients, optionally a temperature check.

ENSURE PATIENT SAFETY

According to WHO recommendations, testing in areas with community transmission must be prioritised and focused on the

early identification and protection of vulnerable patients undergoing surgical procedures¹⁶.

PRE-HOSPITAL TESTING

Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test surgical patients for COVID-19 before the surgical procedure, regardless of risk assessment for COVID-19¹⁶ (Figure 4).

Pre-hospital testing should always be conducted when the patient has symptoms suggestive of SARS-CoV-2 infection and should be considered in case of aerosol generating procedures (AGPs).

When pre-hospital testing is necessary, a period of (self-) isolation has to be taken into consideration according to local practice (i.e., home, hospital). However, other possible scenarios might occur, reflecting different regional and local practices.

In all cases, testing should be paralleled by a thorough collection of epidemiological history, evaluating the occurrence of symptoms of infection in the weeks preceding hospitalisation and the potential contact with an infected patient.

It also seems reasonable that patients wear medical masks during invasive cardiac procedures. This strategy seems reasonable because of the long virus incubation period and viral transmission by asymptomatic or early symptomatic patients^{17,18}.

All other standard practices including accurate hand hygiene, physical distancing whenever possible, and systematic surface and zone disinfection are also essential to ensure both patient and HCW safety¹⁹.

MANAGEMENT OF OUTPATIENT VISITS

Supplementary Table 1 lists precautions for the management of outpatient visits.

For outpatient care, it seems sufficient to investigate symptoms of infection and contacts with infected patients using a questionnaire at the time of phone contact to arrange the date of the visit. It is advisable that patients wear a medical mask during this outpatient visit. However, there should be a strong emphasis on hand hygiene, respiratory hygiene and medical masks to be used by all patients with respiratory symptoms.

In addition, patient visits should be appropriately scheduled to avoid overcrowded waiting rooms, and disabled patients should be assisted by only one person.

Furthermore, for the safety of patients and HCWs, in each clinical scenario presented above, the number of HCWs involved in patient care should be limited to the minimum necessary.

Alternatives to face-to-face outpatient visits should use telemedicine (e.g., telephone consultations or cell phone videoconference) to provide clinical support without direct contact with the patient.

SARS-CoV-2 SWAB AND SEROLOGY TESTS

Clinical interpretation of SARS-CoV-2 swab and serology tests is described in **Table 3**.

Molecular assays for detection of SARS-CoV-2 viral RNA using polymerase chain reaction (PCR)-based techniques or nucleic acid hybridisation strategies can be used to identify




Figure 4. How to guarantee the safety of patients and healthcare workers.

Table 3. Clinical interpretation of SARS-CoV-2 swab and serology tests.

Test result			Possible clinical interpretation
Swab	IgM	IgG	
–	–	–	Negative
+	–	–	Window period
+	+	–	Infection early phase
+	+	+	Infection active phase
+	–	+	Final phase or recurrent infection
–	+	–	Early phase with false-negative swab test
–	–	+	Past infection
–	+	+	Recovery phase

IgG: immunoglobulin G; IgM: immunoglobulin M; Swab: swab testing

SARS-CoV-2-infected individuals during the acute phase of the infection. It is, however, reported that an improperly taken swab may be the cause of a false negative result²⁰. Based on the available studies, a sensitivity of 70% appears to be a reasonable estimate¹⁶. Evaluation of the pre-test probability based on a patient's epidemiological status and perhaps repeated tests could overcome an individual test's limited sensitivity. The sensitivity in asymptomatic individuals is not well established²¹.

A second category includes serological and immunological assays which detect antibodies after exposure to the virus. The detection of specific immunoglobulin M (IgM) anti-SARS-CoV-2

antibodies is possible at the earliest about 10 days after the first clinical symptoms of infection, while immunoglobulin G (IgG) antibodies can be detected even later. The sensitivity of immunoassays may vary from 88.1 up to even 100% depending on the type of test^{22,23}.

An overview of immunoassays and reverse transcriptase-polymerase chain reaction (RT-PCR) diagnostic kits for SARS-CoV-2 is provided in **Supplementary Table 2** and **Supplementary Table 3**.

More recently, rapid antigen detection (RAD) tests for qualitative determination of SARS-CoV-2 antigen also became available (<https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays>). The trade-off is a highly variable sensitivity compared to RT-PCR (ranging from 0-94%), but specificity is consistently reported to be high (>97%). RAD tests are most likely to perform well in patients with high viral loads, as in the pre-symptomatic and early symptomatic phases of the illness, and in populations with expected high prevalence of disease (such as HCWs). However, a negative result cannot completely exclude COVID-19 infection, and therefore in symptomatic patients it might be suggested to repeat testing or preferably conduct confirmatory RT-PCR testing.

It is advisable, if local conditions permit, to maintain swab testing of all patients with real-time RT-PCR-based diagnostic kits detecting SARS-CoV RNA. Nevertheless, which strategy to use will depend on regional and local availabilities and protocols.

ENSURE HCW SAFETY

The safety of HCWs is one of the fundamental aspects of guaranteeing elective invasive procedures during different phases of the pandemic in order to ensure continuity of care to patients with cardiovascular disease. Data from the EAPCI survey show a drastic drop in cardiac procedures and the necessity to improve HCW safety²⁴ and restore confidence amongst HCWs²⁵⁻²⁷. Reports from China and the Hubei region have reported infection rates in HCWs as high as 5.7% which has decreased over time to 2.7% with the use of appropriate protocols, increasing availability of PPE and widespread testing²⁷. However, these rates were observed in front-line HCWs exposed to COVID-19 positive patients. In the elective cardiovascular patient setting, lower numbers are expected. Further studies to report the actual infection rate with routine elective testing are required.

The measures to guarantee HCW safety are illustrated in **Figure 4** and **Figure 5**. PPE plays a crucial role in safe restoration of elective PCI procedures. In the early stage of the pandemic a shortage of such resources was reported, particularly the lack of FFP2/N95 masks and facial protective shields²⁸. However, in patients where COVID-19 is confirmed or suspected, each operator should be equipped with FFP2/N95, eye protection (i.e., face shield or goggles), gloves and gowns, as previously described^{1,16}. Indeed, medical masks might be sufficient when dealing with COVID-19 negative patients and airborne PPE only during AGPs.

Institutional protocols focusing on elective patient admission should be based on local epidemic status and local infrastructure to minimise the risk of admission of an infected patient. However, there are situations in which the maximum level of protection should be maintained (**Figure 5**).




Figure 5. PPE use according to different clinical scenarios.

Testing of HCWs is a resource-intensive measure. Its potential benefit needs to be carefully discussed and will largely depend on the extent of the pandemic and the local situation. In most cases, close attention to clinical symptoms, and routine masking of patients and staff can be more easily and reasonably implemented.

KEY MESSAGES

1. Strategies to prevent SARS-CoV-2 infection should be tailored to the extent and phase of the pandemic of individual regions.
2. Pre-hospital triage is strongly suggested with clear pathways for “hot” and “cold” patients.
3. Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test surgical patients for SARS-CoV-2 infection before the invasive cardiac procedure, regardless of risk assessment for COVID-19.
4. Pre-hospital testing should always be conducted in case of symptoms suggestive of SARS-CoV-2 infection and should be considered in case of AGPs.
5. Patients should wear medical masks during cardiac interventions and outpatient care visits.
6. For HCWs’ PPE, in case of confirmed or suspected COVID-19 positive patients, FFP2/N95 masks are indicated. In case of COVID-19 negative tested patients, medical masks might be sufficient.
7. Regarding testing of HCWs, in most cases close attention to clinical symptoms, and routine masking of patients and staff can be more easily and reasonably implemented.

Conclusions

The COVID-19 pandemic has been associated with a significant decline of elective cardiac procedures to unload HCWs and ICUs but also with an unexpected reduction of primary PCI procedures, with an unusual surge of mechanical complications of STEMI. Elective cardiovascular interventions are now being restored in most regions, though at a different pace depending on the local epidemiology of the pandemic; some countries are already experiencing a second wave or new waves of infections. Recovery plans for elective invasive procedures should consider the interplay between the pandemic stage, the availability of healthcare resources and the priority of specific cardiac disorders. All waiting list patients should be re-prioritised according to clinical criteria (severity of symptoms and disease) with a recurring re-evaluation if necessary (telehealth/outpatient consultation). The decision as to which patient and procedure to prioritise depends on the expected benefit from the procedure, the degree of urgency required and the available resources. Strategies to prevent infection should be tailored on the degree of involvement in the pandemic of individual regions. However, pre-hospital triage is strongly suggested, and clear pathways for “hot” or presumed “hot” patients and “cold” patients are mandatory in each hospital. Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test patients for SARS-CoV-2 infection before the surgical procedure, regardless of risk assessment for COVID-19. Pre-hospital testing should always be conducted in case of symptoms suggestive of SARS-CoV-2 infection and should be considered in case of AGPs. The use of a medical mask during procedures performed in patients with recent negative testing and without symptoms suggestive of COVID-19 disease would be appropriate. The use

of dedicated PPE is indeed advisable before, during, and after procedures performed in elective patients with confirmed and suspected COVID-19 infection.

Acknowledgements

We acknowledge the help of Alessandro Beneduce, MD and Francesca Ziviello, MD in manuscript preparation.

Conflict of interest statement

A. Chieffo declares lecture/consultant fees from Abbott Vascular, Abiomed, Cardinal Health, Biosensors, and Magenta. G. Tarantini declares speaker fees from Edwards Lifesciences, Boston Scientific, and Neovasc Inc. M. Roffi declares institutional research grants from Boston Scientific, Medtronic, Terumo, Biotronik, and GE Healthcare. G. Stefanini declares a research grant from Boston Scientific and speaker fees from Abbott Vascular, Boston Scientific, Biosensors, and B. Braun. P. Buzman declares speaker fees from Novartis and unrestricted research grants from Meril Lifesciences. R. Moreno declares speaker and consultant fees from Amgen, AstraZeneca, Biosensors, Biotronik, Daiichi Sankyo, Edwards Lifesciences, Ferrer, Medtronic, Terumo, Abbott Vascular, Boston Scientific, and New Vascular Therapy. G. Cayla declares personal fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Medtronic, MSD, Pfizer, and Sanofi. A. Baumbach declares institutional research support from Abbott Vascular, and consultation and speaker fees from Abbott Vascular, AstraZeneca, Cardinal Health, Sinomed, MicroPort, KSH, and Medtronic. H. Nef declares speaker fees from Boston Scientific, Abbott, AstraZeneca, Shockwave, SMT and Siemens, consultant fees from Boston Scientific and an institutional grant from SMT. J. Mauri Ferre declares lecture fees from Boston Scientific, Biotronik, Cardiva 2 SL and Medtronic, and consultant fees from Biosensors. M. Voskuil declares institutional research grants from Medtronic, Edwards and Boston Scientific. S. Windecker declares research and educational grants to the institution from Abbott, Amgen, Bristol Myers Squibb, Bayer, Boston Scientific, Biotronik, Cardinal Health, Cardiovalve, CSL Behring, Daiichi Sankyo, Edwards, Johnson and Johnson, Medtronic, Medalliance, Guerbet, Polares, Sanofi, Terumo, V-Wave and Xeltis. The other authors have no conflicts of interest to declare.

References

- Chieffo A, Stefanini GG, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan GL, Gilard M, Halvorsen S, Huber K, James S, Neumann FJ, Möllmann H, Roffi M, Tavazzi G, Mauri Ferré J, Windecker S, Dudek D, Baumbach A. EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. *Eur Heart J*. 2020;41:1839-51.
- Wood DA, Mahmud E, Hourani VH, Sathananthan J, Virani A, Poppas A, Harrington RA, Dearani JA, Swaminathan M, Russo AM, Blankstein R, Dorbala S, Carr J, Virani S, Gin K, Packard A, Dilsizian V, Légaré JF, Leipsic J, Webb JG, Krahn AD. Safe Reintroduction of Cardiovascular Services During the COVID-19 Pandemic: From the North American Society Leadership. *J Am Coll Cardiol*. 2020;75:3177-83.
- Settelmeier S, Rassaf T, Giannitsis E, Münzel T, Breuckmann F. Capacity changes in German certified chest pain units during COVID-19 outbreak response. *Clin Res Cardiol*. 2020;109:1469-75.

- Romaguera R, Cruz-Gonzalez I, Jurado-Román A, Ojeda S, Fernández-Cisnal A, Jorge-Pérez P, Burgos-Palacios V, Ariza-Solé A, López-de-Sa E, and Moreno R. Considerations on the invasive management of ischemic and structural heart disease during the COVID-19 coronavirus outbreak. Consensus statement of the Interventional Cardiology Association and the Ischemic Heart Disease and Acute Cardiac Care Association of the Spanish Society of Cardiology. *REC Interv Cardiol*. 2020;2:112-117.
- De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, Mancone M, Mercurio G, Muscoli S, Nodari S, Pedrinelli R, Sinagra G, Indolfi C; Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. *Eur Heart J*. 2020;41:2083-8.
- Piccolo R, Bruzzese D, Mauro C, Aloia A, Baldi C, Boccalatte M, Bottiglieri G, Briguori C, Caiazzo G, Calabrò P, Cappelli-Bigazzi M, De Simone C, Di Lorenzo E, Golino P, Monda V, Perrotta R, Quaranta G, Russolillo E, Scherillo M, Tesorio T, Tuccillo B, Valva G, Villari B, Tarantini G, Varricchio A, Esposito G; Collaborators. Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syndromes Associated With the COVID-19 Outbreak. *Circulation*. 2020;141:2035-7.
- Moreno R, Alonso JJ, Caballero R, Del Corral E, Elizaga J, Asenjo RM, Mena MJ, Alfonso F, Fernández-Ortiz A, Goicolea FJ, Botas J, Navarro F, Alegría-Barrero E, Ansedé JC, de Sá EL, López-Sendón JL. Influence of age and gender on arrival of patients with ST-segment elevation acute myocardial infarction to tertiary centers during COVID-19 pandemic. Experience of Madrid, Spain, STEMI network (Codigo Infarto Madrid). *Am J Emerg Med*. 2020 Jun 6. [Epub ahead of print].
- Tam CF, Cheung KS, Lam S, Wong A, Yung A, Sze M, Lam YM, Chan C, Tsang TC, Tsui M, Tse HF, Siu CW. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong, China. *Circ Cardiovasc Qual Outcomes*. 2020;13:e006631.
- Roffi M, Guagliumi G, Ibanez B. The Obstacle Course of Reperfusion for ST-Segment-Elevation Myocardial Infarction in the COVID-19 Pandemic. *Circulation*. 2020;141:1951-3.
- Pilz S, Theiler-Schwetz V, Trummer C. Letter by Pilz et al Regarding Article, "Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Elevation Myocardial Infarction Care in Hong Kong, China". *Circ Cardiovasc Qual Outcomes*. 2020;13:e006734.
- Stefanini GG, Montorfano M, Trabattini D, Andreini D, Ferrante G, Ancona M, Metra M, Curello S, Maffeo D, Pero G, Cacucci M, Assanelli E, Bellini B, Russo F, Ielasi A, Tespili M, Danzi GB, Vandoni P, Bollati M, Barbieri L, Oreglia J, Lettieri C, Cremonesi A, Carugo S, Reimers B, Condorelli G, Chieffo A. ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes. *Circulation*. 2020;141:2113-6.
- Chung CJ, Nazif TM, Wolbinski M, Hakemi E, Lebehn M, Brandwein R, Rezende CP, Doolittle J, Rabbani L, Uriel N, Schwartz A, Biviano A, Wan E, Hathaway L, Hahn R, Khalique O, Hamid N, Ng V, Patel A, Vahl T, Kirtane A, Bapat V, George I, Leon MB, Kodali SK. Restructuring Structural Heart Disease Practice During the COVID-19 Pandemic: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2020;75:2974-83.
- Shah PB, Welt FGP, Mahmud E, Phillips A, Kleiman NS, Young MN, Sherwood M, Batchelor W, Wang DD, Davidson L, Wyman J, Kadavath S, Szerlip M, Hermiller J, Fullerton D, Anwaruddin S. Triage considerations for patients referred for structural heart disease intervention during the COVID-19 pandemic: An ACC/SCAI position statement. *Catheter Cardiovasc Interv*. 2020;96:659-63.
- Tarantini G, Masiero G, Nai Fovino L. Impact of a 10 Rules Protocol on COVID-19 Hospital-Related Transmission: Insights From Padua University Hospital, Italy. *Circ Cardiovasc Interv*. 2020;13:e009279.
- Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A,

- Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*. 2019; 40:87-165.
16. WHO. Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed. Geneva: World Health Organization; 2020. <https://www.who.int/publications/i/item/WHO-2019-nCoV-IPC-2020.4>
17. Islam MS, Rahman KM, Sun Y, Qureshi MO, Abdi I, Chughtai AA, Seale H. Current knowledge of COVID-19 and infection prevention and control strategies in healthcare settings: A global analysis. *Infect Control Hosp Epidemiol*. 2020;41:1196-206.
18. Lee S, Meyler P, Mozel M, Tauh T, Merchant R. Asymptomatic carriage and transmission of SARS-CoV-2: What do we know? *Can J Anaesth*. 2020;67:1424-30.
19. Cook TM. Personal protective equipment during the coronavirus disease (COVID) 2019 pandemic - a narrative review. *Anaesthesia*. 2020;75:920-7.
20. Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. *Rev Med Virol*. 2020;30:e2106.
21. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. *N Engl J Med*. 2020;383:e38.
22. Theel ES, Haring J, Hilgart H, Granger D. Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. *J Clin Microbiol*. 2020;58:e01243-20.
23. Vashist SK. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. *Diagnostics (Basel)*. 2020;10:202.
24. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2016;37:267-315.
25. Nadolny K, Ładny J, Zyśko D, Gałzkowski R, Gąsior M, Kraska W. Interventions of emergency medical teams in Poland during the SARS-CoV-2 pandemic. *Kardiol Pol*. 2020 Oct 5. [Epub ahead of print].
26. Gluckman TJ, Wilson MA, Chiu ST, Penny BW, Chepuri VB, Waggoner JW, Spinelli KJ. Case Rates, Treatment Approaches, and Outcomes in Acute Myocardial Infarction During the Coronavirus Disease 2019 Pandemic. *JAMA Cardiol*. 2020;5:1-6.
27. Zhang J, Chen L, Delzell E, Muntner P, Hillegass WB, Safford MM, Millan IY, Crowson CS, Curtis JR. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2014;73:1301-8.
28. Delgado D, Wyss Quintana F, Perez G, Sosa Liprandi A, Ponte-Negretti C, Mendoza I, Baranchuk A. Personal Safety during the COVID-19 Pandemic: Realities and Perspectives of Healthcare Workers in Latin America. *Int J Environ Res Public Health*. 2020;17:2794.

Supplementary data

Supplementary Table 1. Management of outpatient visits.

Supplementary Table 2. Overview of selected immunoassays for SARS-CoV-2.

Supplementary Table 3. Overview of selected reverse transcriptase-polymerase chain reaction diagnostic kits for SARS-CoV-2.

The supplementary data are published online at:

<https://eurointervention.pcronline.com/>

doi/10.4244/EIJ-D-20-01291



Supplementary data

Supplementary Table 1. Management of outpatient visits.

Precautions to prevent transmission	Outpatient visits	TTE	TEE	ExT
Surgical mask for HCW	+	+	+	+
Surgical mask for patient	+	+	-	-
Epidemiological questionnaire	+	+	+	+
Swabs testing	-	-	+	-

ExT: exercise test

Supplementary Table 2. Overview of selected immunoassays for SARS-CoV-2.

	Euroimmun	Epitope	Abbott	Ortho-Clinical	Elecsys
Manufacturer	Euroimmun (Germany)	The Epitope Diagnostics Inc (USA)	Abbott Laboratories (USA)	Ortho-Clinical Diagnostics VITROS (USA)	Roche (Switzerland)
Status	CE-marked	CE-marked	CE-marked	CE-marked	CE-marked
Antibody	IgG/IgA	IgG/IgM	IgG	IgG	IgG/IgM/IgA
Assay principle	ELISA	ELISA	CMIA	CLIA	ECLIA
Specimen type	Serum	Serum	Serum, plasma	Serum	Serum
Antigen	Spike S1	Nucleocapsid	Nucleocapsid	Spike S1	Nucleocapsid
Sample volume	10 µL	10 µL (IgG) 20 µL (IgM)	25 µL	20 µL	20 µL
Positive cut-off	≥ 1.1	≥ 1.21	≥1.4	≥1.0	≥1.0
Time to first result	120 min	80 min	29 min	48 min	18 min
Sensitivity*	97.6 %	88.1 %	92.9%	98.8%	100% **

CLIA: chemiluminescence immunoassay; CMIA: chemiluminescent microparticle immunoassay; ECLIA: electro-chemiluminescence immunoassay; ELISA: enzyme-linked immunosorbent assay; *sensitivity in convalescent sera and in individual patients tested ≥15 days post-symptom onset or first positive SARS

Supplementary Table 3. Overview of selected reverse transcriptase-polymerase chain reaction diagnostic kits for SARS-CoV-2.

	BGI	Viasure	Genesig	RADI PREP	Simplexa
Manufacturer	BGI Genomics (China)	CerTest BIOTEC (Spain)	Primerdesign (UK)	KHMedical (Korea)	DiaSorin (Italy)
Status	CE-marked	CE-marked	CE-marked	CE-marked	CE-marked
Sample type	NPS, BAL	NPS, NS	NPS, NS, sputum	NS, sputum	NS, NPS, NW, BAL
Target gene	ORF1ab	ORF1ab, N	RdRp	RdRp, S	ORF1ab, S
Limit of detection (copy/ml)	4.3	18 (ORF1ab) 4.8 (N)	23	4.8 (RdRp) 4.3 (S)	242
Storage condition	-20°C	Room temperature	-20°C	-20°C	-30°C
Cross-reactivity*	No	No	No	No	No
Time to result	180 min	120 min	-	80 min	60 min
PCR efficiency	117%	99% (ORF1ab) 119% (N)	107%	118%	-

BAL: bronchoalveolar lavage; N: nucleocapsid protein of SARS-CoV-2; NPS: nasopharyngeal swabs; NS: nasal swabs; NW: nasal wash/aspirate; ORF1ab: open reading frame 1a and b of SARS-CoV-2; RdRp: RNA-dependent RNA polymerase. *with confirmed non-coronavirus respiratory viral infections. Van Kasteren PB et al. Comparison of Seven Commercial RT-PCR Diagnostic Kits for COVID-19. J Clin Virol.2020 May 8;128:104412. Bordi L et al. Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexa™ COVID-19 direct assay [published online ahead of print, 2020 May 4]. J Clin Virol. 2020;128:104416.